ZERO tolerance for hypoglycemia
As more and more type 2 diabetics discover the Wheat Belly and other low-carb lifestyles, they are also discovering how rapidly and easily blood sugars drop.
As diabetics become less diabetic–a process that can occur VERY quickly, often within 24 hours of removing all wheat/grains from their diet–but they are taking insulin or certain diabetes drugs, there is potential for hypoglycemia or low blood sugar. Low blood sugar from diabetes drugs can be dangerous and should be avoided at all costs. (Imagine if a non-diabetic started administering insulin or blood sugar-reducing drugs–it would result in life-threate...
Source: Wheat Belly Blog - December 23, 2018 Category: Cardiology Authors: Dr. Davis Tags: News & Updates blood sugar diabetes undoctored wheat belly Source Type: blogs
MKSAP: 64-year-old man with diabetes
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 64-year-old man is evaluated for his quarterly diabetes care follow-up visit. Point-of-care HbA1c level is not at goal for this patient, who has high function, long life expectancy, few comorbidities, good support, health literacy, and access to care. Medical history is significant for hypertension, hyperlipidemia, and obesity. His family history is notable for type 2 diabetes mellitus in his mother and hypertension and chronic kidney disease in his father. Medications are metformin, glipizide, hydrochlorothia...
Source: Kevin, M.D. - Medical Weblog - December 30, 2017 Category: General Medicine Authors: < a href="https://www.kevinmd.com/blog/post-author/mksap" rel="tag" > mksap < /a > Tags: Conditions Diabetes Endocrinology Source Type: blogs
Lactate Intolerant
A 76-year-old woman presented to the ED with altered mental status. Her family said she had increasing fatigue for two days. That morning, the patient had nausea, vomiting, and shoulder pain. EMS found she had a blood glucose of 34. She was given an ampule of D50 and brought to the ED.The patient reported dizziness and fatigue in the ED, and stated that she had not eaten for a few days. Her initial vital signs included temperature 94.1℉, pulse 76 bpm, blood pressure 120/67 mm Hg, respiratory rate 18 bpm, and pulse oximetry 99% on room air. Her physical examination is unremarkable.Initial laboratory values are remarkable ...
Source: The Tox Cave - September 1, 2016 Category: Emergency Medicine Tags: Blog Posts Source Type: blogs
MKSAP: 52-year-old woman with type 2 diabetes mellitus
Test your medicine knowledge with the MKSAP challenge, in partnership with the American College of Physicians.
A 52-year-old woman presents for follow-up evaluation after being diagnosed with type 2 diabetes mellitus 6 weeks ago. Her initial HbA1c level was 8.0%. Management at this time is with lifestyle modifications. She has worked closely with a diabetes educator and a nutritionist since her diagnosis. She has lost 3.2 kg (7 lb) by making changes to her diet and activity level. Review of her blood glucose log for the past 2 weeks shows preprandial blood glucose values in the 150 to 160 mg/dL (8.3-8.9 mmol/L) range and...
Source: Kevin, M.D. - Medical Weblog - June 25, 2016 Category: Journals (General) Authors: mksap Tags: Conditions Diabetes Endocrinology Source Type: blogs
ZERO TOLERANCE for hypoglycemia
Wheat elimination starts you powerfully on the path to reversing diabetes. We’ve seen it many times and it continues to develop in people who kiss their bagels, pretzels, and processed foods booby-trapped with wheat and grains goodbye.
But, as diabetics become less diabetic–a process that can occur VERY quickly, often within days of removing all wheat and grain products from their diet–but they are taking insulin or certain diabetes drugs, there is potential for hypoglycemia or low blood sugar. Low blood sugar from diabetes drugs can be dangerous and should be avoided at all costs. (Imagine if a non-diabetic started ...
Source: Wheat Belly Blog - April 2, 2016 Category: Cardiology Authors: Dr. Davis Tags: Wheat Belly Lifestyle diabetes glucose gluten grains hypoglycemia insulin Source Type: blogs
If you have diabetes: NO low blood sugars!
Wheat elimination starts you powerfully on the path to reversing diabetes. We’ve seen it many times and it continues to develop in people who kiss their bagels, pretzels, and processed foods booby-trapped with wheat goodbye.
But, as diabetics become less diabetic–a process that can occur VERY quickly, often within days of removing all wheat products from their diet–but they are taking insulin or certain diabetes drugs, there is potential for hypoglycemia or low blood sugar. Low blood sugar from diabetes drugs can be dangerous and should be avoided at all costs. (Imagine if a non-diabetic started administ...
Source: Wheat Belly Blog - March 28, 2015 Category: Cardiology Authors: Dr. Davis Tags: Wheat Belly Lifestyle blood sugar diabetes gluten grains hypoglycemia Source Type: blogs
Zero tolerance for hypoglycemia
Wheat elimination starts you powerfully on the path to reversing diabetes. We’ve seen it many times and it continues to develop in people who kiss their bagels, pretzels, and processed foods booby-trapped with wheat goodbye.
But, as diabetics become less diabetic–a process that can occur VERY quickly, often within days of removing all wheat products from their diet–but they are taking insulin or certain diabetes drugs, there is potential for hypoglycemia or low blood sugar. Low blood sugar from diabetes drugs can be dangerous and should be avoided at all costs. (Imagine if a non-diabetic started administ...
Source: Wheat Belly Blog - July 20, 2013 Category: Cardiology Authors: Dr. Davis Tags: Diabetes Source Type: blogs
New Merck R&D Chief Overhauls Operations & Cuts Are Coming
Two months after arriving at Merck as the new head of R&D, Roger Perlmutter is moving quickly to overhaul the operation, which is known as Merck Research Laboratories (back story). As part of the changes, various senior management roles have been eliminated, including franchise heads and site head, and the licensing unit will now report directly to Perlmutter, who is searching for a new head.
"These changes are part of Merck’s existing strategy and ongoing commitment to streamline our operating model and aggressively manage our cost structure,"
a spokesman writes us. "By doing so, we will ensure that we are able to ...
Source: Pharmalot - June 14, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
The ADA's "Investigation" of Incretin Drugs is a Gift to the Drug Companies
You may have heard that the American Diabetes Association (ADA) had called for a review of the incretin drugs--Januvia, Onglyza, Byetta, Victoza, etc.--in response to the recent discovery, which I described HERE, that they cause abnormal patterns of growth within the pancreas of a kind that lead to both pancreatitis and cancer. The call for review can be read HERE.Sadly, this call for review has nothing to do with protecting people with diabetes, a group for whom the ADA has never had much concern, save as a source of contributions to pay the inflated salaries of its top executives.The ADA is heavily funded by drug manufac...
Source: Diabetes Update - June 14, 2013 Category: Diabetes Authors: Jenny Source Type: blogs
Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed? - BMJ
BMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3680 (Published 10 June 2013)
Cite this as: BMJ 2013;346:f3680Article
Related content
Article metrics
Deborah Cohen, investigations editor
Author Affiliations
dcohen@bmj.com
Incretin mimetics have been called “the darlings of diabetes treatment” and they may soon also be licensed for treating obesity. But a BMJ investigation has found growing safety concerns linked to the drugs’ mechanism of action. Deborah Cohenasks why patients and doctors have not been told.
They’ve been touted as th...
Source: PharmaGossip - June 11, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
A Lone Voice Raises Alarms on Lucrative Diabetes Drugs - NYT
LOS ANGELES — Dr. Peter C. Butler initially declined a request by the drug maker Merck to test whether its new diabetes drug, Januvia, could help stave off the disease in rats.“I said, I’m not interested in your money, go away,” Dr. Butler recalled.Merck no doubt now wishes it had. When Dr. Butler finally agreed to do the study, he found worrisome changes in the pancreases of the rats that could lead to pancreatic cancer. The discovery, in early 2008, turned Dr. Butler into a crusader whose follow-up studies now threaten the future of not only Januvia but all the drugs in its class, which have sales of more than $9...
Source: PharmaGossip - May 31, 2013 Category: Pharma Commentators Authors: insider Source Type: blogs
What Patient Harm? FDA Slams Shionogi For Not Preparing Studies
File this under ‘what chutzpah!” Last September, the FDA informed Shionogi that two clinical trials would be required after a serious risk of an irregular heartbeat was associated with its Rybix painkiller. The agency informed the drugmaker that a draft protocol was due this past February and a final report was expected by September 2014.
But last November, Shionogi told the FDA to forget about it. Why? The drugmaker wrote the agency that “the costs of participating in the PMR (post-marketing requirement)… were not commercially justified based on the sales potential for Rybix.” Never mind that patients may have b...
Source: Pharmalot - May 28, 2013 Category: Pharma Commentators Authors: esilverman Source Type: blogs
Three New Drugs for Type 2 Diabetes Approved
By Diane Fennell
On January 26, pharmaceutical manufacturer Takeda announced the approval of its Type 2 diabetes drug, Nesina (generic name alogliptin) by the US Food and Drug Administration (FDA). It is the fourth drug in a class of medicines known as DPP-4 inhibitors, joining Januvia (saxagliptin), Onglyza (sitagliptin), and Tradjenta (linagliptin). Approved simultaneously with Nesina were the drugs Kazano (alogliptin and metformin) and Oseni (alogliptin and pioglitazone [brand name Actos]).
DPP-4 inhibitors work to lower blood glucose by blocking the action of an enzyme known as dipeptidyl peptidase 4, or DPP-4. DPP-...
Source: Diabetes Self-Management - February 8, 2013 Category: Diabetes Authors: Diane Fennell Source Type: blogs
